Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Korro Bio, Inc.NASDAQ: KRRO
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$20.44M, compared with -$25.02M a year earlier. Trailing-twelve-month operating income was -$82.76M.
Context
- Operating income amounted to 1366.4% of revenue in FY2025, down 2680.7 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 6 analysts of -$46.02M (+47.3%) for the fiscal year ending Dec 2026, a step up from the +5.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.44M-28.7% QoQ
- Last fiscal yearDec 2025
- -$87.34M+5.0% YoY
- LTMMar 2026
- -$82.76M+13.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +18.3% | +12.1% | -6.2 pp |
| 1 year | +5.0% | +47.3% | +42.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (87.34M) USD
- Year-over-year change
- +5.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (87.34M) | +5.0% |
| FY2024 | 2024-12-31 | (91.91M) | -8.7% |
| FY2023 | 2023-12-31 | (84.53M) | -43.3% |
| FY2022 | 2022-12-31 | (59M) | +29.8% |
| FY2021 | 2021-12-31 | (84.03M) | — |
Operating Income vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 operating income of -$82.76M is the 5th highest of the 11 companies compared; the peer median is -$91.75M.
- Its year-over-year change of +13.3% is the 4th highest of 9, against a peer median of -5.4%.
- Operating income amounts to 2154.0% of revenue for KRRO, versus a peer median of 9396.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.9M | +178.5% | — | — | |
| LTM Mar 2026 | -$37.36M | +60.7% | — | 17.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$46.86M | — | — | — |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$68.65M | +22.0% | — | — |
| LTM Mar 2026 | -$82.76M | +13.3% | — | 2154.0% | |
| LTM Mar 2026 | -$86.59M | — | — | 9396.6% | |
| LTM Mar 2026 | -$96.92M | +1.3% | — | 269216.7% | |
| LTM Mar 2026 | -$118.62M | -15.4% | — | — | |
| LTM Mar 2026 | -$172.43M | -63.7% | — | — | |
| LTM Mar 2026 | -$172.95M | -49.4% | — | — | |
| LTM Mar 2026 | -$205.06M | -12.1% | — | — | |
| Peer median (excluding KRRO) | -$91.75M | -5.4% | — | 9396.6% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.